A61K 51/1096
Radioimmunotoxins, i.e. conjugates being structurally as defined in a61k51/1093, and including a
Official title: {radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications}
A61K51/1096 (Radioimmunotoxins, i.e. conjugates being structurally as defined in a61k51/1093, and including a) appears on 193 US grants and 444 published applications in this corpus.
Search patents in A61K- Granted patents
- 193
- Published applications
- 444
- Assignees
- 190
- Inventors
- 753
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 2 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 3 | 0 |
| 2002 | 0 | 2 |
| 2003 | 1 | 4 |
| 2004 | 1 | 14 |
| 2005 | 0 | 6 |
| 2006 | 3 | 4 |
| 2007 | 4 | 3 |
| 2008 | 6 | 5 |
| 2009 | 0 | 6 |
| 2010 | 5 | 8 |
| 2011 | 3 | 6 |
| 2012 | 4 | 4 |
| 2013 | 7 | 9 |
| 2014 | 8 | 25 |
| 2015 | 17 | 16 |
| 2016 | 17 | 29 |
| 2017 | 9 | 23 |
| 2018 | 13 | 15 |
| 2019 | 8 | 21 |
| 2020 | 8 | 26 |
| 2021 | 7 | 15 |
| 2022 | 19 | 36 |
| 2023 | 10 | 42 |
| 2024 | 8 | 66 |
| 2025 | 18 | 29 |
| 2026 | 9 | 30 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Urokinase plasminogen activator receptor-targeted radiopharmaceutical22 Sep 2026US 12,741,039 B2Monopar Therapeutics Inc.
- Combination therapy for treating cancer25 Aug 2026US 12,714,759 B2City of Hope
- Stabilized radiolabeled anti-CD45 immunoglobulin compositions18 Aug 2026US 12,708,678 B2Actinium Pharmaceuticals, Inc.
- Calreticulin nanobodies30 Jun 2026US 12,668,622 B2Actinium Pharmaceuticals, Inc.
- Radiolabeling of anti-CD45 immunoglobulin and methods of use thereof21 Apr 2026US 12,605,472 B2Actinium Pharmaceuticals, Inc.
- In vivo imaging of an als biomarker and means therefor8 Oct 2026US 2026/0306683 A1AL-S Pharma AG
- Anti-bdca2 antibody24 Sep 2026US 2026/0285985 A1Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Combined Therapy with Nanoparticles and Radiopharmaceuticals3 Sep 2026US 2026/0256963 A1Centre National De La Recherche Scientifique
- Humanised Anti Kallikrein-2 Antibody3 Sep 2026US 2026/0258157 A1Janssen Biotech, Inc.
- Reagents and methods for imaging cancers expressing pdgfralpha20 Aug 2026US 2026/0241050 A1Eli Lilly and Company
Most cited
By later US patents
- Covalently-linked complexes and methods for enhanced cytotoxicity and imaging241US 5,169,933 ANeoRx Corporation · 1992
- Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides112US 6,309,636 B1Cancer Research Institute of Contra Costa · 2001
- Methods to impair hematologic cancer progenitor cells and compounds related thereto72US 6,733,743 B2University of Kentucky Research Foundation · 2004
- Antibody therapy71US 7,662,378 B2Immunomedics, Inc. · 2010
- Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases67US 8,420,086 B2Immunomedics, Inc. · 2013